TScan Therapeutics Stock Forecast
NASDAQ: TCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 1:59 PM ET
TCRX analyst consensus
Consensus (5 analysts)
hold
Avg. price target
$1.00+329.37%
- Strong buy 0
- Buy 1
- Hold 4
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering TScan Therapeutics (2026-10-09), 1 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $1.00, with a high estimate of $1.00 and a low estimate of $1.00. The average target implies upside of 329.4% from the current price of $0.2329.
The spread between the highest and lowest targets is 0.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for TCRX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 20% |
| Hold | 4 | 80% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.00 | +329.37% |
| Average target | $1.00 | +329.37% |
| High target | $1.00 | +329.37% |